MEMPHASYS LIMITED. — Capital/Financing Update 2020

Sep 8, 2020

ASX Release 9 September 2020

ASX Code: MEM

==> picture [222 x 64] intentionally omitted <==

$1.29 million R&D Rebate Received

Australian-based bio-separations company Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to announce receipt of a A$1,293,092 tax rebate following the submission of its 2020 R&D Tax Incentive claim.

The R&D Tax Incentive scheme is a program jointly administered by the Australian Taxation Office and AusIndustry, under which companies can receive a refundable tax offset of eligible expenses on research and development activities.

The receipt of R&D Tax rebate follows the Company’s continued research & development activity associated with the Felix[TM] device, a unique instrument with proprietary, patented technology for quickly separating high quality sperm from a semen sample for use in human IVF procedures.

The tax rebate has been received at an important time for the Company as Memphasys looks to accelerate commercialisation ahead of first sales of the Felix device.

This announcement has been approved for release by the board of Memphasys Limited.

ENDS

For further information please contact:

Alison Coutts David Tasker Executive Chairman Managing Director Memphasys Limited Chapter One Advisors T: +61 2 8415 7300 T: +0433 112 936 E:alison.coutts@memphasys.com E: dtasker@chapteroneadvisors.com.au

About Memphasys:

Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company’s patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.

Website: www.memphasys.com